| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18...
Cantor Fitzgerald analyst Olivia Brayer reiterates Gossamer Bio (NASDAQ:GOSS) from Overweight to Overweight.
UBS analyst Eliana Merle upgrades Gossamer Bio (NASDAQ:GOSS) from Neutral to Buy and raises the price target from $1.25 to $9.
Wedbush analyst Laura Chico maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and raises the price target from $4 to $5.
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) ...